DeuteRx
Andover
About DeuteRx
DeuteRx is a research and development-focused biotechnology company dedicated to improving racemic small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications. The company specializes in the use of deuterium to chiral switch drugs that are a mixture of interconverting stereoisomers. This approach has been applied to >15 APIs at 2 companies since 2010.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.8M
- Funding stage: Seed
- Last round: Seed (Sep 2015)
- Website: deuterx.com
- Phone: (978)662-5287
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/deuterx-2220647 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.